Sera Prognostics, Inc. (NASDAQ:SERA) Short Interest Update

Sera Prognostics, Inc. (NASDAQ:SERA) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 844,400 shares, a decrease of 19.6% from the December 31st total of 1,050,000 shares. Based on an average daily trading volume, of 102,700 shares, the days-to-cover ratio is currently 8.2 days. Currently, 4.0% of the shares of the company are sold short.

Insider Buying and Selling

In other news, General Counsel Benjamin Jackson sold 13,272 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $7.42, for a total transaction of $98,478.24. Following the completion of the sale, the general counsel now directly owns 128,473 shares of the company’s stock, valued at $953,269.66. This trade represents a 9.36 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Zhenya Lindgardt sold 12,075 shares of Sera Prognostics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $7.32, for a total value of $88,389.00. Following the completion of the transaction, the chief executive officer now directly owns 819,758 shares in the company, valued at $6,000,628.56. This represents a 1.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 93,215 shares of company stock worth $666,835 in the last three months. 15.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Jane Street Group LLC increased its stake in Sera Prognostics by 24.8% in the third quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock valued at $111,000 after acquiring an additional 2,826 shares during the period. American Century Companies Inc. grew its holdings in shares of Sera Prognostics by 12.7% during the second quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock worth $152,000 after purchasing an additional 2,891 shares during the last quarter. Rhumbline Advisers increased its position in Sera Prognostics by 10.6% in the 4th quarter. Rhumbline Advisers now owns 36,101 shares of the company’s stock valued at $294,000 after acquiring an additional 3,468 shares in the last quarter. Quest Partners LLC increased its holdings in shares of Sera Prognostics by 533.5% in the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after purchasing an additional 5,415 shares in the last quarter. Finally, MetLife Investment Management LLC increased its stake in shares of Sera Prognostics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 17,254 shares of the company’s stock valued at $135,000 after buying an additional 9,722 shares during the period. Institutional investors and hedge funds own 54.64% of the company’s stock.

Sera Prognostics Stock Performance

Shares of Sera Prognostics stock traded down $0.18 during trading on Friday, hitting $6.47. 112,445 shares of the stock traded hands, compared to its average volume of 92,625. The stock has a market cap of $218.49 million, a P/E ratio of -6.54 and a beta of 0.86. The company has a fifty day moving average price of $7.36 and a two-hundred day moving average price of $7.36. Sera Prognostics has a twelve month low of $4.98 and a twelve month high of $12.35.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same period last year, the firm earned ($0.23) EPS. On average, equities research analysts expect that Sera Prognostics will post -0.96 EPS for the current fiscal year.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.